Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for Hard-to-Treat prostate cancer? drug combo trial begins

NCT ID NCT06616155

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 21 times

Summary

This study tests a combination of two drugs, ruxolitinib and enzalutamide, in men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to find the safest dose and see if the combo can shrink tumors or lower PSA levels. About 39 participants will take part in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for STAGE IVB PROSTATE CANCER AJCC V8 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Karmanos Cancer Institute

    NOT_YET_RECRUITING

    Detroit, Michigan, 48201, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Rush University

    NOT_YET_RECRUITING

    Chicago, Illinois, 60612, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • University of Michigan Comprehensive Cancer Center

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.